Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Halozyme Therapeutics, Inc.
April 21 2014 - 2:02PM
Business Wire
Shareholder rights law firm Johnson & Weaver, LLP has
commenced an investigation into whether certain officers and
directors of Halozyme Therapeutics, Inc. (NASDAQ: HALO) violated
state or federal laws. Halozyme is a biopharmaceutical company
that researches, develops and commercializes human enzymes.
On April 9, 2014, Halozyme announced that the U.S. Food and Drug
Administration had placed a clinical hold on patient enrollment and
dosing of PEGPH20 in patients with pancreatic cancer. Just a few
days earlier on April 4, 2014, Halozyme issued a statement
announcing that the Phase 2 trial for PEGPH20 would be
halted. The suspension of the trial followed the
recommendation of an independent Data Monitoring Committee (DMC)
while it assesses "clinical data that indicates a possible
difference in the thromboembolic event rate between the group of
patients treated with PEGPH20, nab-paclitaxel and gemcitabine
versus the group of patients treated with nab-paclitaxel and
gemcitabine without PEGPH20." Since April 4, 2014, Halozyme shares
have fallen $4.02, or 35%, to close at $7.57 on April 17, 2014.
If you are a Halozyme shareholder and are interested in
learning more about the investigation or your legal rights and
remedies, please contact Jim Baker
(jimb@johnsonandweaver.com) at 619-814-4471. If you
email, please include your phone number.
Johnson & Weaver, LLP is a nationally recognized shareholder
rights law firm with offices in California and New York. The firm
represents individual and institutional investors in shareholder
derivative and securities class action lawsuits. For more
information about the firm and its attorneys, please visit
http://www.johnsonandweaver.com. Attorney advertising. Past results
do not guarantee future outcomes.
Johnson & Weaver, LLPJim Baker,
619-814-4471jimb@johnsonandweaver.com
Halozyme Therapeutics (NASDAQ:HALO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Halozyme Therapeutics (NASDAQ:HALO)
Historical Stock Chart
From Apr 2023 to Apr 2024